Vaxigriptetra®

BIOLOGICAL2 trials

Sponsors

Assistance Publique - Hôpitaux de Paris, Sanofi

Conditions

InfluenzaMorbid ObesitySevere Obesity

Phase 3

Trial Assessing the Immunogenicity and Safety of Two Influenza Vaccine Strategies Among Severe Obese Adult Patients

CompletedNCT05409612

Assistance Publique - Hôpitaux de ParisMorbid Obesity, Severe Obesity

Start: 2022-11-07End: 2023-10-03Updated: 2024-02-26

Unknown Phase

Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra®) in Subjects Aged 6 to 35 Months

CompletedNCT05832333

SanofiInfluenza

Start: 2019-10-05End: 2022-02-07Updated: 2023-04-27

Related Papers

Recombinant vs Standard Influenza Vaccine in Adults With Severe Obesity: A Randomized Clinical Trial.

2026-03-19